Mh. Rhee et al., CANNABINOL DERIVATIVES - BINDING TO CANNABINOID RECEPTORS AND INHIBITION OF ADENYLYLCYCLASE, Journal of medicinal chemistry, 40(20), 1997, pp. 3228-3233
Several derivatives of cannabinol anti the 1,1-dimethylheptyl homolog
(DMM) of cannabinol were prepared and assayed for binding to the brain
and the peripheral cannabinoid receptors (CB1 and CB2), as well as fo
r activation of CB1- and CB2-mediated inhibition of adenylylcyclase. T
he DMH derivatives were much more potent than the pentyl (i.e., cannab
inol) derivatives. 11-Hydroxycannabinol (4a) was found to bind potentl
y to both CB1 and CB2 (K-i values of 38.0 +/- 7.2 and 26.6 +/- 5.5 nM,
respectively) and to inhibit CB1-mediated adenylylcyclase with an EC5
0 of 58.1 +/- 6.2 nM but to cause only 20% inhibition of CB2-mediated
adenylylcyclase at 10 mu M. It behaves as a specific, though not poten
t, CB2 antagonist. 11-Hydroxycannabinol-DMH (4b) is a very potent agon
ist for both CB1 and CB2 (K-i values of 100 +/- 50 and 200 +/- 40 pM;
EC50 of adenylylcyclase inhibition 56.2 +/- 4.2 and 207.5 +/- 27.8 pM,
respectively).